Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jan 6, 2021; 9(1): 71-80
Published online Jan 6, 2021. doi: 10.12998/wjcc.v9.i1.71
Published online Jan 6, 2021. doi: 10.12998/wjcc.v9.i1.71
Primary lung cancer with radioiodine avidity: A thyroid cancer cohort study
Yu-Ling Lu, Shu-Fu Lin, Department of Internal Medicine, New Taipei Municipal TuCheng Hospital, New Taipei City 236, Taiwan
Yu-Ling Lu, Szu-Tah Chen, Shu-Fu Lin, Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan
Szu-Tah Chen, Shu-Fu Lin, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
Tsung-Ying Ho, Department of Nuclear Medicine, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan
Wen-Hui Chan, Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan
Wen-Hui Chan, Institute for Radiological Research, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
Richard J Wong, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, United States
Chuen Hsueh, Department of Pathology, Chang-Gung Memorial Hospital, Taoyuan 333, Taiwan
Author contributions: Lin SF designed the study; Hsueh C performed the immunohistochemical study; all authors analyzed and interpreted the data; Lu YL wrote the first draft of this manuscript; Chen ST, Ho TY, Chan WH, Wong RJ, Hsueh C and Lin SF reviewed and revised the manuscript.
Supported by Chang Gung Memorial Hospital , No. CMRPG3J0471 ; and US NIH/NCI Cancer Center Support Grant , No. P30 CA008748 .
Institutional review board statement: The present study was approved by the Chang Gung Medical Foundation Institutional Review Board (No. 202000365B0) and was conducted in accordance with the ethical principles of the Helsinki Declaration.
Informed consent statement: Informed consent was waived by Chang Gung Medical Foundation Institutional Review Board.
Conflict-of-interest statement: The authors report no relevant conflicts of interest.
Data sharing statement: The authors confirm that the data supporting the findings of this study are available within the article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shu-Fu Lin, MD, Doctor, Department of Internal Medicine, New Taipei Municipal TuCheng Hospital, No. 2 Jingcheng Road, New Taipei City 236, Taiwan. mmg@cgmh.org.tw
Received: September 17, 2020
Peer-review started: September 17, 2020
First decision: October 18, 2020
Revised: October 30, 2020
Accepted: November 13, 2020
Article in press: November 13, 2020
Published online: January 6, 2021
Processing time: 105 Days and 20.9 Hours
Peer-review started: September 17, 2020
First decision: October 18, 2020
Revised: October 30, 2020
Accepted: November 13, 2020
Article in press: November 13, 2020
Published online: January 6, 2021
Processing time: 105 Days and 20.9 Hours
Core Tip
Core Tip: A radioiodine (RAI) scan is usually performed to detect the existence of differentiated thyroid cancer (DTC). A proportion of lung cancers demonstrate sodium/iodide symporter (NIS) expression. Lung cancers with NIS expression may be able to uptake RAI and show RAI-avid lesions on RAI scan, leading to misinterpretation upon performing this test for DTC surveillance. Single-photon emission computed tomography/computed tomography provides morphologic characterization of the functional tumor, improving diagnostic accuracy over RAI scan.